Xspray Pharma AB publishes its Annual Report for 2024

REG

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2024.

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:

“In 2024, we finalized the foundation for Xspray Pharma’s transformation from an innovative, research-driven company into a commercial drug company. We have addressed regulatory challenges, conducted market preparations and secured funding to launch our first product, Dasynoc®, in the US market in 2025.”

The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.

Datum 2025-03-27, kl 08:00
Källa MFN
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.